Keywords: UCB, Lectus Theapeutics, CNS portfolio

UCB adds to CNS portfolio with acquisition of Lectus’ key pharmaceutical assets

Article | 23 November 2011

Belgian drugmaker UCB (Euronext Brussels: UCB) has acquired the key pharmaceutical assets of closely-held, UK based drug developer Lectus Therapeutics ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

UCB

Lectus Therapeutics

Go to company listing